

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification <sup>6</sup> : <b>A61K 47/26, C07K 1/00, C12N 9/96</b></p>		A1	<p>(11) International Publication Number: <b>WO 95/33488</b> (43) International Publication Date: 14 December 1995 (14.12.95)</p>		
<p>(21) International Application Number: <b>PCT/GB95/01277</b></p>		<p>(81) Designated States: CN, JP, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</p>			
<p>(22) International Filing Date: 2 June 1995 (02.06.95)</p>					
<p>(30) Priority Data: 08/252,967 2 June 1994 (02.06.94) US</p>		<p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>			
<p>(71) Applicant: QUADRANT HOLDINGS CAMBRIDGE LIMITED [GB/GB]; Maris Lane, Trumpington, Cambridge CB2 2SY (GB).</p>					
<p>(72) Inventors: ROSER, Bruce, Joseph; The Old Vicarage, Church Lane, Balsham, Cambridge CB1 6DS (GB). COLACO, Camilo; 107 Foster Way, Trumpington, Cambridge CB2 2JN (GB). KAMPINGA, Jaap; Grevingaheerd 9, NL-9737 SB Groningen (NL). SMITH, Christopher; 37 A Woodend, Bluntisham, Huntingdon, Cambridgeshire PE17 3LE (GB).</p>					
<p>(74) Agent: GOLDIN, Douglas, Michael; J.A. Kemp &amp; Co., 14 South Square, Gray's Inn, London WC1R 5LX (GB).</p>					
<p>(54) Title: METHOD OF PREVENTING AGGREGATION OF VARIOUS SUBSTANCES UPON REHYDRATION OR THAWING AND COMPOSITIONS OBTAINED THEREBY</p>					
<p>(57) Abstract</p> <p>Methods of reducing or preventing aggregation of a wide variety of substances, (e.g. colloids, red blood cells, pharmaceuticals) during freezing/thawing or dehydrating/rehydrating are disclosed whereby trehalose is added to a solution or suspension of the substance before freezing or dehydrating.</p>					

BEST AVAILABLE COPY

# BEST AVAILABLE COPY

## FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

- 1 -

METHOD OF PREVENTING AGGREGATION OF  
VARIOUS SUBSTANCES UPON REHYDRATION OR  
THAWING AND COMPOSITIONS OBTAINED THEREBY

5 Field of the Invention

The present invention relates to methods of preventing the formation of aggregates of various substances upon dehydration and rehydration and upon freezing and thawing. Compositions obtained thereby are also encompassed by the  
10 invention.

Background of the Invention

Storage and processing of a wide range of substances in a dehydrated or frozen form is necessary to retain  
15 activity, prevent degradation products from forming and to facilitate handling and transport. Unfortunately, upon rehydration or thawing, many substances tend to aggregate, thereby decreasing their effective concentration and often rendering them useless or forming harmful byproducts.

20 Various methods have been tried to prevent or eliminate such aggregation. For instance, detergents and chaotropic agents are often used to prevent aggregation of proteins in solution. These agents are thought to prevent aggregation mediated by hydrophobic interactions and thus  
25 are limited to prevention of aggregation due to this cause. See, e.g., Tanford and Reynolds (1976) *Biochim. Biophys. Acta.* 457:133; and Tanford, "The Hydrophobic Effect", 2nd Ed., Wiley, N.Y. (1980). Such agents may also not be suitable for use where the substances are to be formulated  
30 into therapeutic compositions as they may cause adverse reactions.

Aluminium salts in solution are in the form of a highly  
hydrated colloidal gel and carry a surface charge at any pH  
35 outside their isoelectric point. Since each colloidal particle carries the same charge, they mutually repel each other and thus naturally form a stable colloidal gel. When

- 2 -

the hydration shell is removed (e.g., by freezing or drying) the particles can contact each other and the surface energy causes aggregation.

Trehalose,  $\alpha$ -D-glucopyranosyl- $\alpha$ -D-glucopyranoside, is a naturally occurring, non-reducing disaccharide which was initially found to be responsible for protection of intact plant cells from desiccation. Trehalose has been shown to be useful in preventing denaturation of proteins viruses and foodstuffs during desiccation. U.S. Patent 5 Nos. 4,891,319; 5,149,653; 5,026,566; Blakeley et al. 10 (1990) Lancet 336:854-855; Roser (1991) Trends in Food Sci. and Tech. pp.166-169; Colaco et al. (1992) Biotechnol. Internat., pp. 345-350; Roser (1991) BioPharm. 4:47-53; and Colaco et al. (1992) Bio/Tech. 10:1007-1011.

15 In the field of protein purification it would be particularly useful to eliminate or prevent the tendency of, eg. proteins, to aggregate upon rehydration and thawing. This is especially important in the area of biopharmaceuticals where the proteins are often used as an 20 ongoing basis of treatment. In the case where protein aggregates form and are injected into a patient, antibodies may form to the protein which diminish the effectiveness of the treatment. Thus, it would be useful to prevent aggregation of a wide variety of substances particularly 25 those useful in medicine.

Summary of the Invention

The invention encompasses a method of reducing aggregation during dehydration and rehydration of substances comprising the steps of adding to a solution or 5 suspension of the substances an amount of trehalose sufficient to prevent aggregation upon rehydration; and dehydrating the solution or suspension. The invention also encompasses the compositions obtained thereby.

The invention further encompasses rehydrating the 10 solution or suspension to obtain a composition substantially lacking aggregates of the substance. The compositions obtained thereby are also encompassed by the invention.

The invention further encompasses a method of reducing 15 aggregation of substances in solution or suspension during freezing (and optionally thawing) comprising the steps of adding to the solution or suspension of the substance an amount of trehalose sufficient to prevent aggregation during freezing; and freezing the solution or suspension. 20 The invention also comprises the compositions obtained thereby.

The invention further comprises the step of thawing the frozen solution or suspension to obtain a composition substantially lacking aggregates of the substance. The 25 compositions obtained thereby are also encompassed by the invention.

A wide variety of substances are suitable for use in the invention including, but not limited to, therapeutic, prophylactic and diagnostic.

30 When the substance is red blood cells, the method may further comprise the step of fixing the red blood cells prior to adding trehalose. Fixing of red blood cells can be done by any known method including, but not limited to, formaldehyde and glutaraldehyde.

35

Brief Description of the Drawings

- 4 -

Figure 1 is a bar graph depicting the percent height of sedimentation of aluminium phosphate per column after 24 hours. Columns labeled with + and - symbols were dried in the presence and absence of trehalose respectively. T<sub>v</sub> stands for vacuum drying, T<sub>fd</sub> stands for freeze drying, T<sub>fz</sub> stands for freezing, T<sub>4fz</sub> stands for freeze thawing four times and T<sub>w</sub> stands for aqueous samples.

Figure 2 is a bar graph depicting the percent height of sedimentation of aluminium phosphate per column after 5.5 hours. Prior to testing, samples were stored for one week at 45°C. The abbreviations are the same as those in Figure 1.

Figure 3 is a bar graph depicting the percent height of sedimentation of aluminium hydroxide after 24 hours. The numbers refer to the series as described in Example 3, d stands for vacuum drying, w stands for aqueous control, and f stands for freezing.

#### Detailed Description of the Invention

The present invention encompasses a method of reducing aggregation during dehydration and rehydration of substances by adding to an eg. aqueous solution or suspension of the substances an amount of trehalose sufficient to prevent aggregation upon rehydration; and dehydrating the solution or suspension.

The invention further encompasses a method of reducing aggregation of substances in an eg. aqueous solution or suspension during freezing and thawing comprising the steps of adding to the solution or suspension of the substance an amount of trehalose sufficient to prevent aggregation during freezing and thawing; and freezing the solution or suspension.

The invention also relates to eg. aqueous compositions containing trehalose in order to prevent or reduce aggregation, including frozen and dehydrated compositions.

The term "aggregation" as used herein refers to the interaction of two or more molecules of a substance such

- 5 -

that they no longer behave as monomers but as dimers, trimers or other multimeric forms. Reducing aggregation decreases the concentration of multimeric forms compared to substances dehydrated and rehydrated or frozen and thawed

5 in the absence of trehalose. A substance substantially free of aggregates or substantially nonaggregated is one which, upon rehydration or thawing, contains a decreased amount of multimeric forms of the substance compared to a control lacking trehalose. Typically, trehalose prevents

10 the formation of all multimeric forms of the substance. In the case of growth hormone, for instance, the addition of trehalose prior to dehydrating or freezing can result in the elimination of all multimeric forms with the exception of dimers. The dimers are, however, reduced in comparison

15 to a control.

In a preferred embodiment, the substances suitable for use in the invention have medical utility. Such substances include, but are not limited to, therapeutic substances, prophylactic substances and diagnostic substances. The

20 substances can be those which form multimers upon dehydration/rehydration and/or freezing/thawing. The method of formation of multimers or aggregates is not critical to the invention.

Suitable therapeutic substances include, but are not limited to, any therapeutically effective biological modifier. Such modifiers include, but are not limited to, proteins and peptides, steroid hormones, oligosaccharides, nucleic acids, polynucleotides and a variety of small molecules. Further, the modifiers may be derived from

25 natural sources made by recombinant or synthetic means and include analogues, agonists and homologs. As used herein "protein" refers also to peptides and polypeptides. Such proteins include, but are not limited to, growth hormones, growth factors, insulin, monoclonal antibodies, interferons

30 and interleukins. Preferably, the growth hormone is human growth hormone. Suitable steroid hormones include, but are not limited to, estrogen, progesterone and testosterone.

- 6 -

Therapeutic substances prepared by the methods described herein are also encompassed by the invention.

Suitable prophylactic substances include, but are not limited to, aluminium based adjuvants such as aluminium hydroxide and aluminium phosphate which are used in preparation of vaccines. Compositions containing the, eg. prophylactic, substances are further encompassed by the invention. Preferred compositions include vaccines containing the aluminium hydroxide or aluminium phosphate prepared by the method described herein. Suitable vaccines include, but are not limited to, combination vaccines, such as diphtheria, tetanus, pertussis (DTP) or DTP/inactivated poliovaccine (IPV). Suitable diagnostic substances include, but are not limited to, colloidal gold, polystyrene latex, fixed erythrocytes and monoclonal antibodies. Diagnostic substances and compositions prepared by the method described herein are also encompassed by the invention.

The dehydration step can be performed by any method known in the art including, but not limited to, lyophilization, drying at ambient conditions or drying under reduced vapor pressure. When drying at reduced vapor pressure, the temperature at which the drying occurs is preferably below the temperature at which degradation of the substance occurs.

The freezing step can be performed by any method known in the art including, but not limited to immersing in liquid nitrogen, placing in a freezer which may be at -4°C to -80°C, dry ice and alcohol freezing bath. The samples should be maintained at a temperature suitable to maintain the frozen state. Thawing the frozen sample can be by any means known in the art, for instance at room temperature or at an elevated temperature. If thawing occurs at an elevated temperature, the temperature should be below that which causes denaturation or other chemical changes in the substance. Optimal freezing and thawing temperatures can

be determined empirically. Such a determination is within the skill of one in the art.

Once the substances have been dehydrated or frozen, they can be stored indefinitely. The dehydrated substances 5 can store well at ambient temperatures, although they may be stored at any temperature below that which causes denaturation or other chemical changes. The invention further includes rehydration of the dehydrated samples to obtain solutions and suspensions substantially free of 10 aggregates of the substance. Rehydration may add at least an amount of water sufficient to restore the buffer composition of the original solution or suspension but may add any amount of water or buffer.

When the substance comprises red blood cells, the 15 method may further comprise fixing the red blood cells prior to adding trehalose. The fixing step may be done by any method known in the art including, but not limited to, glutaraldehyde. In the preferred embodiment, the cells are fixed.

20 The methods of the present invention prefer that the trehalose be present in an amount sufficient to prevent or reduce aggregation of the substance upon rehydration or thawing. Such a determination will be made empirically and is well within the skill of one in the art. Preferably, 25 trehalose is added in an amount to obtain a final concentration of from about 1% to 50% (w/v). More preferably, trehalose is added in an amount to obtain a final concentration of from about 5% to 25% (w/v).

Trehalose is available from a variety of suppliers. 30 Preferably the grade of trehalose used is ANALAR reagent, molecular biology or pharmaceutical grade. In the case of medicinal compositions the trehalose preferably meets the good manufacturing practice (GMP) standards set by the Food and Drug Administration (FDA).

35 The invention also encompasses the products obtained by the method both before and after rehydration or thawing. In one embodiment, the invention includes the frozen

- 8 -

compositions containing a substance and an amount of trehalose sufficient to prevent aggregation of the substance upon thawing. In another embodiment, the invention includes a dehydrated composition comprising a 5 substance and an amount of trehalose sufficient to prevent aggregation of the substance upon rehydration. The invention further includes the compositions after being thawed or rehydrated respectively.

The invention additionally encompasses the use of 10 trehalose as an aggregation reducing or preventing agent, particularly for substances present in an (eg. aqueous) composition such as a solution or suspension of that substance.

Interestingly, the amount of trehalose found to be 15 effective at preventing aggregation cannot be directly extrapolated from the amount of trehalose effective in preventing desiccation damage. For instance, work presented in United States Patent No. 4,891,319 showed that amounts of trehalose as low as 1% w/v in a protein solution 20 could prevent desiccation damage to proteins such as Factor VIII. The Examples presented herein show that more than 30% w/v trehalose is necessary to completely prevent aggregation of aluminium hydroxide and 15% w/v is necessary to prevent aggregation of a protein.

25 The following examples are meant to illustrate, but not limit, the invention.

- 9 -

EXAMPLES

Example 1

Prevention of Aggregation of Particulate

Suspensions by Trehalose

5 In order to determine whether trehalose prevented aggregation of particulate suspensions, two examples, colloidal gold and polystyrene latex, were studied. Colloidal gold was obtained from the Babraham Laboratories and polystyrene latex was a suspension of particles of 10 polystyrene which had been purchased from Sigma Chemical Company.

The colloidal gold was made according to the method described by Frens (1993) Nature 241:20. It was dried from a concentrated suspension of 0.2% Au in a volume of 50  $\mu$ l 15 per well in a 96 well microtiter plate either with added 10% w/v trehalose or without trehalose and subsequently rehydrated after storage for one week at 37°C in a dry oven. On rehydration, the material that had been dried in the presence of trehalose gave a smooth suspension of 20 colloidal gold as determined by microscopic examination. The material that had been dried without trehalose showed microscopic aggregates which could not be broken up into a smooth suspension.

With the polystyrene latex, similar experiments were 25 conducted. The latex was obtained from Sigma Chemical Company catalogue number LB-8, average diameter 0.8 micron polystyrene. It was used at the concentration obtained from the supplier and again was dried without any addition of, and also with the addition of, 10% w/v trehalose which 30 was dissolved in the solution before drying. Both samples were rehydrated about a week after drying and were stored at 37°C in a dry oven in the interim. The material dried without trehalose was badly aggregated into very large clumps. The material dried in the presence of trehalose 35 resuspended into a very smooth, single particulate suspension.

- 10 -

Thus, the addition of trehalose prior to drying the particulate suspensions substantially reduced the amount of aggregation upon rehydration compared to a control lacking trehalose.

5

Example 2

Effect of Trehalose-Drying  
on Aggregation of Red Blood Cells

10 Experiment

Rat RBCs were washed three times in an anti-coagulant CPD (102 mM trisodium citrate, 1.08 mM sodium phosphate and 11 mM dextrose), filtered through cotton wool and fixed in either 1% formaldehyde or 0.5% glutaraldehyde. Fixing was 15 at room temperature for one hour. The fixed cells were washed three times in CPD and resuspended in either 10% trehalose and 0.12 mM sodium azide (NaN<sub>3</sub>) or CPD. The final cell concentration was 25% w/v.

Cells fixed in formaldehyde lysed on washing and were 20 not processed further.

Unfixed cells agglutinated in trehalose and needed the addition of 1/5th volume of phosphate-buffered saline before being processed further.

Then 100  $\mu$ l of cells in either 10% trehalose 0.12 mM 25 NaN<sub>3</sub>, or CPD were dried either in Nunc plates or on slides and examined microscopically for aggregates.

Results

The unfixed cells dried without trehalose lysed 30 completely and with those dried with trehalose also showed 95-99% lysis though the ghosts showed discoid morphology.

The fixed cells dried without trehalose showed gross macroscopic aggregation of the cells. The fixed cells dried with trehalose resuspended as a smooth single cell 35 suspension with only a few microaggregates. These microaggregates appear to form at higher concentrations of

- 11 -

trehalose and thus do not appear to be concentration dependent.

Example 3

5       Aggregation of Aluminium Hydroxide and Phosphate

Sedimentation Assay

The following method was followed to determine whether trehalose was successful in preventing aggregation of 10 prophylactic adjuvants.

Aluminium phosphate and aluminium hydroxide were diluted 5-fold to a final concentration of 0.6% w/v and allowed to sediment in 1 ml glass pipettes. The height of the sediment column was measured at various time intervals 15 up to 24 hours. Note that the % height of sediment column should not be < 30% when a steady state has been reached (about 5 hours.)

The samples were dried under vacuum, frozen at -20°C and thawed at room temperature.

20

Results

Pilot 1. Aluminium phosphate

Different forms of drying and storage were compared in the presence or absence of 15% trehalose. These were 25 vacuum drying (Tv), freeze drying (Tfd), freezing (Tfz) and freeze thawing for four cycles (T4fz). Wet controls (Tw) which were stored at 4°C were also run.

Then 200  $\mu$ l sample per glass vial were dried and sedimentation assays carried out at day 0 and after 1 week 30 storage at 45°C. The results obtained are shown in Figures 1 and 2.

Pilot 2. The aggregation of aluminium hydroxide and haemaccel (degraded gelatin) was measured with a titration of trehalose with the concentrations shown in Table 1. The 35 samples contained 1.5% aluminium hydroxide and 2% haemaccel. Only vacuum drying (d) and freezing (f) were compared. Wet controls (w) contained trehalose and

- 12 -

haemaccel but were not dried or frozen. Each series contained (d), (f) and (w) samples. The concentrations used are shown in Table 1 and the results obtained are shown in Figure 3.

5

Table 1

<u>Series</u>	<u>Final % trehalose</u>	<u>% haemaccel</u>
1	7.5	-
2	15	-
10 3	30	-
4	15	2
5	-	-

Conclusions

15 a) 15% trehalose can prevent freezing induced aggregation in aluminium phosphate and aluminium hydroxide

b) 7.5% trehalose is not sufficient for preventing aggregation during the drying process.

20 c) No additional effect of Haemaccel at 2% was observed.

Aluminium hydroxide, dried in the absence of trehalose and rehydrated was found to be aggregated into large clumps 25 which sedimented rapidly and quickly to yield a very small gel column. Trehalose in concentrations above 15% prevented this aggregation so that the rehydrated material formed a gel column of a height similar to the fresh, undehydrated material. This sedimentation pattern 30 illustrates that the hydrated, nonaggregated molecules have a large hydration shell volume and are separated from one another causing them to sediment slowly.

Example 4

35 Effect of Trehalose on  
Aggregation of Biological Molecules

- 13 -

Protein formulations may undergo modification by a number of mechanisms including deamidation, oxidation and aggregation, the principle causes of human growth hormone (hGH) degradation. Deamidation and oxidation are 5 considered collectively as chemical degradation. To date there is little evidence of any effect of these chemical degradation products on biopotency. Pearlman and Bewly (1993) In: Wang and Pearlman eds. Stability and Characterization of Protein and Peptide Drugs, pp. 1-58, 10 Plenum Press, New York.

Aggregation is the principle problem affecting hGH and other protein formulations used as biopharmaceuticals and may reduce biopotency. Soluble or insoluble aggregates can form as a result of both covalent and non-covalent 15 interactions. A variety of stresses such as heating, freezing or agitation may induce aggregation. Whilst a visible insoluble aggregate may render a parenteral product unuseable, the major problem is the induction of an unwelcome immune response in the subject (Pearlman and 20 Bewley, 1993). This is particularly detrimental where the protein formulations such as hGH are administered parenterally and in multiple doses.

The following experiment was performed to determine whether or not trehalose affected the aggregation of 25 proteins. Samples of hGH (5 mg) were dried from 200  $\mu$ l containing 15% trehalose, 5 mM  $\text{Na}_2\text{HPO}_4$  -  $2\text{H}_2\text{O}$  adjusted to pH 7.4 with  $\text{H}_3\text{PO}_4$  (formulation A). Two control samples were prepared: 5 mg hGH dried from 200  $\mu$ l sodium phosphate buffer pH 7.4 (formulation B); and 5 mg hGH dried from 200 30  $\mu$ l sodium phosphate buffer pH 7.4, 5 mg glycine, 25 mg mannitol (formulation C). These formulations were dried for 20 hours in a vacuum drier at a pressure of 30 millitorr and a shelf temperature of 40°C. They were subsequently sealed under vacuum in standard pharmaceutical 35 serum vials with rubber closures and a crimped aluminium seal.

- 14 -

Following storage at 40°C in a dry incubator, samples were rehydrated with deionised water and analysed by reverse phase and size exclusion high performance liquid chromatography to determine chemical degradation and 5 aggregation respectively according to the method described by Pikal et al. (1991) Pharm. Res. 8:427-436. These results are presented in Table 2.

Formulation A was subsequently re-analysed and compared with a conventionally freeze-dried essentially as 10 described in Pikal et al. (1991) equivalent formulation (formulation D). These results are presented in Table 3.

### Results

An accelerated aging protocol of four weeks at 40°C 15 was utilized to assess stability and aggregation. The formulation containing trehalose performs very well under these conditions. No chemical degradation was observed and the limited aggregation detected was restricted to dimer formulation (Table 2, lines 1-4). The absence of high 20 molecular weight aggregates is significant.

Two hGH controls were formulated, one without a stabilizing excipient (B) and one containing glycine and mannitol that was similar to commercial formulations (C) (Table 2, lines 5-6). These formulations suffered from 25 considerable chemical degradation and aggregate formation, both dimer and higher molecular weight. The values for the glycine mannitol formulation were comparable with results from a previous study in which a similar formulation was freeze-dried (Table 3, line 7, Pikal, et al. 1991). When 30 the stability of formulation A was compared with that of a freeze-dried equivalent (formulation D), no difference in terms of 40°C stability was observed (Table 3, lines 1-6). In Tables 2 and 3 chemical degradation is measured by the area under the curve represented by the deamidated protein. 35 Thus the hGH formulations containing trehalose, either dried at 40°C or freeze-dried, have been shown to be considerable improvements on previous formulations.

- 15 -

Table 2  
Summary of hGH Stabilization and Aggregation Data  
(Part 1)

5	Line	Formulation	Treatment	% Chemical Degradation	% Aggregation Dimer	% Aggregation High Mol. Weight
	1	A	pre-dry	3.1	0.4	0.003
	2	A	post-dry	3.3	0.6	0.06
10	3	A	2wk., 40°C	3.5	0.9	0.02
	4	A	4wk., 40°C	3.4	1.1	0.002
	5	B	4wk., 40°C	11.1	6.9	2.1
	6	C	4wk., 40°C	8.2	2.2	0.8

15

Table 3  
Summary of hGH Stabilization and Aggregation Data  
(Part 2)

20	Line	Formulation	Treatment	% Chemical Degradation	% Aggregation
	1	A	initial	4.15	0.66
	2	A	2wk., 40°C	4.16	0.92
	3	A	4wk., 40°C	4.25	1.04
25	4	D	initial	4.05	0.71
	5	D	2wk., 40°C	4.09	0.86
	6	D	4wk., 40°C	4.17	0.92
	7	E	4wk., 40°C	8.2	3.0

30

Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity and understanding it will be apparent to those skilled in the art that certain changes and modifications may be practiced. Therefore, the description and examples should not be construed as limiting on the invention, which is delineated by the appended claims.

- 16 -

CLAIMS

1. A method of reducing or preventing aggregation during dehydration and rehydration of a substance, the  
5 method comprising:

adding to a solution or suspension of the substance an amount of trehalose sufficient to prevent or reduce aggregation upon rehydration; and  
dehydrating the solution or suspension.

10

2. A method according to claim 1 further comprising rehydrating the substance to obtain a solution or suspension of the substance in a substantially nonaggregated form.

15

3. A method of reducing or preventing aggregation of a substance in solution or suspension during freezing, the method comprising:

adding to the solution or suspension of the substance an amount of trehalose sufficient to reduce or prevent aggregation during freezing; and  
freezing the solution or suspension.

4. A method according to claim 3 further comprising  
25 thawing the solution or suspension to obtain a solution or suspension of the substance in a substantially nonaggregated form.

5. A method according to any preceding claim wherein  
30 the substance is a therapeutic, prophylactic or diagnostic substance.

6. A method according to claim 5 wherein the substance is a therapeutic substance and is a biological  
35 response modifier.

- 17 -

7. A method according to claim 6 wherein the biological modifier is a protein, peptide, steroid hormone, oligosaccharide, nucleic acid, polynucleotide or a small molecule.

5

8. A method according to claim 7 wherein the protein is a growth hormone, growth factor, insulin, monoclonal antibody, interleukin or interferon.

10

9. A method according to claim 8 wherein the substance is human growth hormone.

10. A method according to claim 7 wherein the steroid hormone is estrogen, progesterone or testosterone.

15

11. A method according to claim 5 wherein the substance is a prophylactic substance and is an aluminium based adjuvant.

20

12. A method according to claim 11 further comprising incorporating the adjuvant into a vaccine.

25

13. A method according to claim 12 wherein the vaccine is a diphtheria/tetanus/pertussis (DTP) or diphtheria/tetanus/pertussis/inactivated poliovaccine (DTP/IPV).

14. The method according to claim 13 wherein the vaccine is DTP or IPV.

30

15. A method according to any preceding claim wherein the substance is a diagnostic substance and is colloidal gold, a polystyrene latex, fixed erythrocytes or a monoclonal antibody.

35

- 18 -

16. A method according to any preceding claim wherein the trehalose is added in an amount to obtain a final concentration of from 1% to 50% (w/v).

5 17. A method according to any preceding claim wherein the trehalose is added in an amount to obtain a final concentration of from 5% to 25% (w/v) .

10 18. A method according to any of claims 15 to 17 wherein the substance is red blood cells and the method further comprises fixing the red blood cells prior to adding trehalose.

15 19. A method according to claim 18 wherein the fixing is by glutaraldehyde.

20 20. A method according to any of claims 1, 2 or 5 to 19 wherein dehydration occurs by lyophilization, drying at ambient conditions or drying under reduced vapor pressure.

25 21. A method according to claim 20 wherein the drying at reduced vapor pressure occurs at room temperature or at a temperature elevated above room temperature but below a temperature at which degradation or chemical change of the substance occurs.

22. A composition obtained by a method according to any preceding claim.

30 23. An aqueous composition comprising a substance and an amount of trehalose sufficient to reduce or prevent substantial aggregation of the substance upon freezing and thawing or dehydrating and rehydrating.

35 24. A frozen composition comprising a substance and an amount of trehalose sufficient to reduce or prevent substantial aggregation of the substance upon thawing.

- 19 -

25. A dehydrated composition comprising a substance and an amount of trehalose sufficient to reduce or prevent aggregation of the substance upon rehydration.

5 26. A composition according to any of claims 23 to 25 which is a therapeutic, prophylactic or diagnostic composition.

10 27. Use of trehalose to reduce or prevent aggregation of a substance upon freezing and thawing or dehydrating and rehydrating in a solution or suspension of that substance.

1/3




FIG. 1

2/3




FIG. 2

3/3




FIG. 3

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/GB 95/01277

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 6 A61K47/26 C07K1/00 C12N9/96

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 6 A61K C07K C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO,A,90 04329 (COULTER CORP) 3 May 1990 see page 4, line 1 - line 29 see page 7, line 20 - line 30; claims 12-16 ---	1-27
X	WO,A,90 13637 (HYGEIA SCIENCES LTD) 15 November 1990 see page 16, line 20 - page 17, line 9 ---	1-27
Y	US,A,5 026 566 (ROSER BRUCE J) 25 June 1991 cited in the application	1-27
X	see the whole document ---	22-26
Y	US,A,4 891 319 (ROSER BRUCE J) 2 January 1990 cited in the application	1-27
X	see the whole document ---	22-26
	-/-	

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

\* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

19 October 1995

Date of mailing of the international search report

22. 11. 95

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl.  
Fax (+ 31-70) 340-3016

Authorized officer

Foerster, W

BEST AVAILABLE COPY

# BEST AVAILABLE COPY

## INTERNATIONAL SEARCH REPORT

Internat. Application No  
PCT/GB 95/01277

### C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US,A,5 242 792 (RUDOLPH ALAN S ET AL) 7 September 1993 see column 3 - column 4 -----	1-27

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

Internati	Application No
PCT/GB 95/01277	

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO-A-9004329	03-05-90	US-A-	5059518	22-10-91
		AU-B-	633029	21-01-93
		AU-B-	4411889	14-05-90
		CA-A-	1335362	25-04-95
		EP-A-	0444159	04-09-91
		IE-B-	62544	08-02-95
		JP-T-	4501112	27-02-92
WO-A-9013637	15-11-90	US-A-	5102788	07-04-92
		EP-A-	0470192	12-02-92
		JP-T-	5500854	18-02-93
US-A-5026566	25-06-91	AU-B-	614977	19-09-91
		AU-B-	1988288	30-01-89
		CA-A-	1332033	20-09-94
		DE-A-	3870332	27-05-92
		EP-A, B	0297887	04-01-89
		FI-B-	94826	31-07-95
		WO-A-	8900012	12-01-89
		GB-A, B	2206273	05-01-89
		IE-B-	60308	29-06-94
		JP-T-	2503864	15-11-90
		SU-A-	1816199	15-05-93
US-A-4891319	02-01-90	AU-B-	591160	30-11-89
		AU-B-	6136386	30-01-87
		DE-A-	3682047	21-11-91
		DK-B-	170173	06-06-95
		EP-A, B	0229810	29-07-87
		WO-A-	8700196	15-01-87
		GB-A-	2187191	03-09-87
		JP-B-	7079694	30-08-95
		JP-T-	63500562	03-03-88
US-A-5242792	07-09-93	NONE		

**BEST AVAILABLE COPY**

THIS PAGE BLANK (USPTO)